The development of immunosuppressive drugs has in recent years been focused on prevention of acute rejection. This has led to an increase in one-year allograft survival. However, these drugs have non-immune effects which contribute to the high incidence of late graft loss, as a consequence of chronic allograft nephropathy, and the death of patients. As an immune-specifi c alternative to conventional immunosuppressants, new biotechnology tools have been developed; they target the costimulation signal of T-cell activation, particularly by the "classical" B7/CD28 and CD40/CD40L pathways. Here, we review the limitations of current immunosuppressive protocols, the benefi ts of classical B7/CD28 costimulation blockade, and the fi rst large-scale clinical application of this strategy to human transplantation with belatacept. We will also consider novel costimulatory molecules of the B7/CD28 and TNF/TNF-R families, which appear to be important for the functions of memory and effector T-cells.
New immunosuppressive drugs have greatly decreased the frequency of graft failure due to acute rejection, but have had little effect on the incidence of late graft loss due to chronic allograft nephropathy or on patient deaths (Meier-Kriesche et al 2004) . This is largely due to the broad non immune effects of current immunosuppressive drugs, the targets of which are ubiquitous and non specifi c. Progress has recently been made in dissecting the T-cell/antigen presenting cell (APC) interactions and, in particular, the costimulation pathways critical for T-cell activation. Biotechnology has developed new tools -monoclonal antibodies and fusion proteins -targeting the relevant molecules very precisely.
Here we review the limitations of current immunosuppressive protocols, the benefi ts of classical B7/CD28 costimulation blockade, and its fi rst large-scale application with belatacept. We will also address novel costimulatory molecules of the B7/CD28 and TNF/TNF-R families, which appear to be particularly important for the functions of memory and effector T-cells. These categories of T-cells play important roles in allograft rejection and are less susceptible to classical costimulation blockade (London et al 2000) .
Limitations of current immunosuppressive protocols
Because there is a relationship between acute rejection and late allograft failure, the recent development of immunosuppressive drugs has been focused on the prevention of acute rejection. Thus, with the introduction of cyclosporine in the early 1980s and newer immunosuppressive drugs in the 1990s (tacrolimus, mycophenolate mofetil or MMF and sirolimus), the incidence of acute rejection has substantially decreased to 10 to 30% (Denton et al 1999) . Consequently, one-year allograft survival has increased: according to the OPTN/SRTR report, the adjusted one-year graft survival for recipients of deceased non-extended criteria donor kidneys was 91% (Cohen et al 2006) . However, contrary to the optimistic projections for the 1988-1995 period (Hariharan et al 2000) , actuarial analysis has revealed only a small increase in graft half-lives: from 6 years in 1988 to 8 years in 1995 (Meier-Kriesche et al 2004) . Chronic allograft nephropathy (CAN) and death of transplant patients with a functioning graft are the main causes of late allograft failure. The broad non immune effects of current immunosuppressive drugs (see Table 1 ) contribute to both CAN and the risk of patient death.
Death of patients with functioning graft
Death with a functioning graft accounts for 50% of late allograft failure (Pascual et al 2002) , and 43% of such cases are due to cardiovascular events (West et al 1996) . The following factors are frequently encountered in renal transplant patients and contribute to cardiovascular diseases: older age, obesity, hypertension, diabetes mellitus, hyperlipidemia, smoking, long-term chronic renal failure and dialysis. Patients may present these factors before transplantation, but some are frequent side effects of currently used immunosuppressive drugs (Table 1) . Other causes of death include infection and cancer, often associated with a generally high immunosuppressive burden rather than the direct effect of a single molecule. An exception is the lower incidence of cancers observed in patients treated with mTOR inhibitors -sirolimus and everolimus -because of their anti-proliferative effect on several types of malignancies (Kauffman et al 2005) .
Chronic allograft nephropathy
CAN is a pathological fi nding on kidney biopsy; it consists of fi brosis and tubular atrophy, and the clinical presentation is often a gradual decrease in GFR associated with proteinuria and hypertension (Pascual et al 2002) . CAN is not a single pathogenic entity but most frequently the result of combined immunological and nonimmunological manifestations ( Table 2) .
The immunological factors include episodes of acute cellular rejection and also sub-clinical acute rejections defi ned as histological evidence of acute cellular rejection from routine kidney biopsies (those performed not because of a deterioration of renal function). The recent histological characterization of antibody-mediated rejection (AMR) with C4d staining and the detection of donor-specifi c antibodies (DSA) with sensitive techniques have indicated the role of humoral immunity in acute and chronic rejection (Snanoudj et al 2005) . Circulating DSA are present in many (100% in some series) patients with histological evidence of chronic rejection and in 50% of cases, these antibodies appear de novo after transplantation (Lee et al 2002) . Moreover, among patients with de novo DSA, the rate of graft failure after one year is 8.6%, whereas it is only 3.0% for patients without these antibodies (Terasaki and Ozawa 2004) .
The non immunological features include classic conditions that increase the rate of decline of renal function in all nephropathies (diabetes, hypertension, hyperlipidemia, obesity). The "quality" of the donor is becoming a critical issue. Indeed, because of the shortage of organs and the growing demand, kidneys are currently procured from elderly deceased donors, donors with pre-existing hypertension, diabetes, cardio-vascular risk factors or disease, and mild renal failure. These grafts are called "extended-criteria donor (ECD) kidneys" (Rosengard et al 2002) . The clinical outcome with these kidneys is better than that with dialysis, but some studies have shown a higher risk of late allograft failure compared with allografts procured from non-marginal donors. For the same reasons, kidneys harvested from non heart-beating donors are being transplanted more frequently than in the past, despite the risk of delayed graft The benefits afforded by CNI in terms of short-term survival, makes their detrimental effects on long-term survival diffi cult to study. Nankivell et al performed repeated biopsy protocols over 10 years with 120 kidney-pancreas transplant patients receiving cyclosporine or tacrolimus. They showed that histological lesions associated with CNI nephrotoxicity (arteriolar hyalinosis with vascular narrowing, stripped-band fi brosis) increase with time after transplantation and become universal by ten years; these lesions constitute the chief cause of late injury and decline in renal function (Nankivell et al 2003) .
Because of the long-term nephrotoxicity of CNI, their metabolic side-effects and the resulting risk of CAN and death of patients, recent immunosuppressive protocols tend to minimize or even avoid the use of CNI. It is now clear that complete withdrawal of CNI from the gold standard triple therapy (with steroids and MMF) results in a signifi cant increase in the rate of late acute rejection. Nevertheless, it seems reasonable, with MMF as anti-proliferative drug, to use lower doses of CNI than previously with azathioprine (Ekberg et al 2007) . However, how much long-term toxicity can be reduced by this approach remains to be determined (Kaplan and Budde 2007 ). An attractive alternative to CNI is costimulation blockade and the possibility for precise Tcell targeting, which could protect patients from many of the side-effects common with classical immunosuppressants.
Immunological basis of the co-stimulation blockade T-cell activation by three signals (Table 3) . However, the B7/CD28 and CD40/CD40L pathways are probably the most important and best characterized in T-cell activation. The costimulation signal is delivered when B7-1/CD80 and B7-2/CD86 on the surface of DCs engage CD28 on T-cells (Bromley et al 2001) . These two signals activate three transduction pathways (Halloran 2004 ) that result in the production of numerous factors, including interleukin-2 (IL-2) and the α-chain of its receptor, CD25, and the CD40 Ligand. CD40 is expressed on all APCs (including B cells) and its ligand (CD40L or CD154) is on activated CD4
+ T-cells and on a subset of CD8 + T-cells and NK cells. CD40 stimulation triggers important signals for antibody production by B cells and strongly induces B7 and MHC expression on APCs. The CD40/CD40L system thus amplifi es antigen presentation and the fi rst antigen-specifi c signal (van Kooten and Banchereau 1997) .
IL-2 binding to its receptor activates the mTOR ("target of rapamycin") pathway -the third signal -resulting in T-cell clonal proliferation and in the generation of effector T-cells (Halloran 2004 ).
The B7/CD28/CTLA-4 pathway
This pathway is characterized by the dual specifi city of two B7 family members, B7-1 and B7-2, for both the stimulatory receptor CD28 and the inhibitory receptor CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4/CD152). CD28 provides a T-cell activation signal, and CTLA-4 inhibits T-cell responses (Table 3 ) (Greenwald et al 2005) . CD28 is constitutively expressed on T-cells, whereas CTLA-4 expression is rapidly upregulated following T-cell activation. CTLA-4 has a higher receptor affi nity for both B7-1 and B7-2 than CD28. Recently, a new regulatory mechanism was demonstrated for DCs, through B7/CTLA-4 reverse signaling (meaning from T-cell to DC) (Finger and Bluestone 2002; Grohmann et al 2002) . CTLA-4, when binding to B7, may activate the immunosuppressive pathway of tryptophan catabolism in DCs (Grohmann et al 2002) . This pathway consists of the production by DCs of Interferon-γ, which stimulates the indoleamine 2,3-dioxygenase (IDO) to degrade tryptophan. The resulting degradation products and tryptophan deprivation inhibit Tcells proliferation and promote their apoptosis. These two-way B7/CTLA-4 interactions may be involved in the inhibition of T-cell responses. Work with a model of murine islet allografts shows that the long-term survival induced by CTLA4-Ig -a fusion protein of CTLA-4 with an immunoglobulin -depends on effective tryptophan catabolism and that this effect disappears in the presence of 1-methyltryptophan, a pharmacological inhibitor of IDO (Grohmann et al 2002) . However, Pree et al found divergent results regarding the role of IDO in vivo (Pree et al 2007) . They tested costimulation blockade as a component of murine bone marrow transplantation protocol for the induction of mixed chimerism and donor-specifi c skin graft tolerance. They demonstrated that induction of high-level chimerism and permanent skin engraftment obtained with CTLA4-Ig occurred independently of IDO. Indeed, chimerism and graft survival were not affected by implantation of pellets releasing 1-methyltryptophan. The use in this study of the human construct of CTLA4-Ig abatacept, which may have different binding properties than the murine fusion protein, may explain this divergence.
B7/CTLA-4 interactions and regulatory T-cells
A subgroup of CD4 + CD25 + T-lymphocytes, termed regulatory or suppressor T-lymphocytes (T-reg), are central to the establishment of transplantation tolerance in several experimental models (Graca et al 2002) . Their clinical signifi cance in human transplantation is currently being investigated. Muthukumar et al (2005) found that urinary levels of FOXP3 mRNA, a functional factor specifi c to T-regs, were inversely correlated with serum creatinine at the time of acute rejection. Moreover, levels of FOXP3 mRNA were signifi cantly higher in the group with successful reversal of acute rejection than in the group without reversal. The patients in higher third of FOXP3 mRNA level had the lowest rate of graft failure following an acute rejection episode. In sum, this study suggests that FOXP3-expressing T-regs play a role in the limitation of alloimmune response and that the lack of suppression exerted by these cells during an episode of acute allograft rejection increases the risk of incomplete resolution and graft loss. (Muthukumar et al 2005) . Moreover, this fi nding has potential for the identifi cation of patients at risk of graft failure after an episode of rejection. The lack of expression of B7-1 and B7-2 on the surface of effector cells results in lower susceptibility to suppression exerted by CD4 + CD25
+ T-cells. Indeed, direct contact between suppressor and effector cells is required in vitro, through the binding of CTLA-4 on T-reg and B7-1/B7-2 on effector cells. (von Boehmer 2005) . In vivo suppression also requires B7 expression on effector cells. In a skin transplant model, blockade of the CTLA-4 pathway abolishes immunoregulation by CD4 + CD25 + T-cells, suggesting that CTLA-4 is required for tolerance (Kingsley et al 2002) .
Experimental models of "classical" costimulation blockade
The B7/CD28 pathway One of the fi rst tools used to target the B7/CD28 pathway was the CTLA4-Ig molecule, a fusion protein consisting of the extracellular domain of CTLA-4 and the Fc domain of IgG. CTLA4-Ig may act by directly disrupting B7/CD28 crosstalk and/or by activating the immunosuppressive pathway of tryptophan catabolism in DCs (see above) (Grohmann et al 2002) . CTLA4-Ig effi ciently prevents acute heart or kidney rejection in many mouse and rat models (Turka et al 1992; Glysing-Jensen et al 1997; Sayegh et al 1995 Sayegh et al , 1997 . In some animal models, it inhibits the T-cell-dependent antibody response and prevents the progression of chronic rejection (Azuma et al 1996; Judge et al 1996) . However, it induces long-lasting tolerance in only a few models of heart or kidney transplantation (Lenschow et al 1992; Sayegh et al 1995; Yamada et al 2001; Ito et al 2005) , and not in more stringent models, such as mouse skin and islet transplantation (Trambley et al 1999; Rothstein et al 2001; Sho et al 2005) . Transplantation tolerance is used to indicate that a single administration of an immunosuppressant at the time of transplantation is suffi cient to ensure an indefi nite donor-specifi c graft survival. The inability of CTLA4-Ig to generate such tolerance may be the consequence of various factors: 1. Costimulation blockade is less effective in memory T-cells and effector CD8 + T-cells than in naïve T-cells (Onodera et al 1997; Trambley et al 1999; Valujskikh et al 2002) .
2. CTLA4 plays a key role in downregulating T-cell responses, independently of CD28/B7 blockade. CTLA-4 signaling is essential for initial engraftment (Judge et al 1999; Sho et al 2002) . Moreover, in the absence of CD28-mediated costimulation (CD28-defi cient animals), interaction of CTLA-4 with B7 results in down-regulation of alloimmune response and prolongation of allograft survival. The blockade of CTLA-4/B7 interactions with CTLA-4-Ig or blocking anti-CTLA-4 antibodies abolishes the prolongation allograft survival observed in these animals (Yamada et al 2001) . 3. Suppression of the alloimmune response requires a functional CTLA-4/B7 pathway between T-reg and effector cells (see above) (Kingsley et al 2002; Paust et al 2004) .
The CD40/CD40L pathway Similar to CD28/B7, the blockade of the CD40/CD40L pathway with an anti-CD40L mAb rarely results in durable tolerance when used alone (Parker et al 1995; Hancock et al 1996; Larsen et al 1996 Larsen et al , 2005 . The effects of anti-CD40L mAb are reversible, so prolonged administration is often required (Kirk et al 1999) . However, simultaneous CD40/ CD40L and B7/CD28 blockade may promote indefi nite graft survival, even in stringent models such as mouse skin transplantation and xenotransplantation (Larsen et al 1996; Elwood et al 1998; Li et al 1999) .
Costimulation blockade in non-human primates
Non-human primate (NHP) models must be used to make the jump from small animal models to clinical protocols. In adolescent rhesus monkeys, kidney graft survival increases from 8 days to 30 days when CTLA4-Ig is used alone and to up to six months if CTLA4-Ig plus humanized anti-CD40L antibody (hu-anti-CD40L) are used (Kirk et al 1997) . Survival was similar with hu-anti-CD40L antibody alone, suggesting that CD40/CD40L pathway blockade is critical (Elster et al 2001) . Treatment did not prevent chronic rejection as routine biopsies on day 28 showed, in all animals, donor-specifi c antibodies and focal perivascular infi ltrate (Kirk et al 1999) . Delivery of the fi rst signal without costimulation signal drives T-cells to a state of anergy (Schwartz 1990; Lombardi et al 1994) . New protocols, based upon the suppressor properties of these anergic T-cells, can improve the results of costimulation blockade in NHPs. In human bone marrow transplantation, the treatment of donor bone marrow ex vivo with CTLA4-Ig and its coculture with irradiated recipient-cells to induce donor-specifi c anergic T-cells before its re-injection to the recipient resulted in a low risk of graftversus-host-disease (Guinan et al 1999) . Similarly, in NHP models, when recipient splenic T-cells are cocultured with irradiated donor splenocytes in the presence of both antihuman CD80 and CD86 mAbs and re-injected into recipient, graft survival was indefi nite in 50% of cases (Bashuda et al 2005) . The simplicity, safety and effi cacy of this protocol make it suitable for application to human transplantation.
Development of LEA29Y (belatacept) and fi rst clinical trial in renal transplantation
It can be diffi cult to transpose experimental fi ndings in NHPs to human clinical trials, because primates lack "heterologous immunity". Indeed, the animals used are raised in captivity and have limited exposure to non-self antigens; consequently they may not have an extensive repertoire of effector/memory cells (Elster et al 2004) .
Preliminary clinical results with CD40 pathway targeting
The fi rst agent used to block costimulation in human trials was huC58, a humanized anti-CD40L antibody. This agent was well tolerated in NHPs but its development for human use was discontinued after seven patients suffered unanticipated thromboembolic events (Kawai et al 2000) . This complication refl ects the importance of costimulatory molecule expression by non-lymphoid cells. Indeed, CD40L has been detected on the surface of activated platelets and has been shown to activate endothelium. Moreover, the absence of CD40L affects the stability of arterial thrombi and delays arterial occlusion in vivo, in a CD40-independent manner (Andre et al 2002) . This antibody was not able to prevent acute rejection in 5 of 7 seven kidney transplant patients in a phase I trial (Vincenti 2002) . Thus, targeting CD40 rather than its ligand was considered as an alternative, so as to avoid these thromboembolic complications. A chimeric anti-human CD40 antibody, Chi220, has recently been developed to circumvent these adverse events. It has proved particularly effective in combination with CTLA4-Ig for islet transplantation in NHPs, with the property of transiently depleting B cells .
Development of LEA29Y
Similar to the CD40/CD40L pathway, the two components of the B7/CD28 pair have been targeted with biological immunosuppressive agents. h1F1 and h3D1 are two humanized antibodies directed against CD80 and CD86, respectively, which have been shown to inhibit CD28-dependent T-cell proliferation in vitro. In vivo, provided that both mAbs are used together, they prolong kidney allograft survival in NHPs (Hausen et al 2001) . At phase I clinical trial stage, in combination with steroids, cyclosporine and mycophenolate mofetil, they proved to be safe and effective. However, they were subsequently withdrawn from further development, despite the good safety profi le, for fi nancial reasons (Vincenti 2002) .
CTLA4-Ig (abatacept) is a fusion protein consisting of the extracellular domain of CTLA-4 and the Fc domain of IgG. The affi nity of CTLA4-Ig for CD80 is 200 times higher than that for CD86 and it is 100 times more potent for the blockade of CD80-dependent costimulation than for that of CD86-dependent costimulation (Linsley et al 1994) . Insuffi cient blockade of CD28/B7 interaction may partly account for the limited results obtained in NHP models. However, treatment with CTLA4-Ig is associated with a signifi cant clinical improvement of T-cell-mediated autoimmune conditions, including psoriasis and rheumatoid arthritis (Abrams et al 1999; Kremer et al 2003) .
A mutagenesis and screening strategy using various CTLA4-Ig variants has been used to identify high-avidity mutants with slower dissociation rates . Two amino-acid substitutions in the binding domain (L104E and A29Y) were identifi ed as potentially useful, leading to the development of a new molecule, LEA29Y or belatacept. Its binding avidity to CD80 and CD86 was twofold and fourfold higher, respectively, and inhibition of T-cell activation was tenfold more powerful than those of CTLA4-Ig. NHPs studies showed a prolongation of kidney allograft survival and an inhibition of anti-donor humoral response when belatacept was used alone or in combination with steroids and MMF .
First clinical trial with belatacept in renal transplantation
A large-scale 12-month study has been conducted to assess the effi cacy of a strategy based upon costimulation blockade with belatacept in renal transplantation (Vincenti et al 2005) . This phase 2 multicenter study included 218 adult kidney recipients at low immunological risk, randomly assigned to receive an intensive regimen of belatacept, a less-intensive regimen, or cyclosporine A (CsA). Belatacept was administered as peripheral intravenous injections each lasting 30 minutes. Both belatacept regimens included an early phase of 10 mg/kg body weight injections every two weeks, and a late phase of 5 mg/kg injections (at four-week or eightweek intervals). For the intensive regimen, the early phase involved 11 injections over 6 months and the less intense regimen involved 5 injections over 3 months. Patients of all three groups also received basiliximab induction therapy, mycophenolate mofetil and steroids.
The primary non-inferiority objective was reached, with the following incidences of acute rejection at six months: 6% (less-intensive belatacept), 7% (intensive belatacept) and 8% (CsA). Subclinical rejection at month-12 routine biopsy was more common with less-intensive belatacept (20 %) than with intensive belatacept (9 %) or cyclosporine (11%). The glomerular fi ltration rate measured with iohexol clearance at 12 months was signifi cantly higher in patients receiving belatacept than in those treated with CsA (66.3 and 62.1 versus 53.5 ml/min/1.73 m 2 ). By month 12, the incidence of chronic allograft nephropathy as assessed from protocol biopsy was lower in patients receiving belatacept: 29% (less intensive) and 20% (intensive) versus 44% in the cyclosporine arm. Four patients in the cyclosporine arm died (two from cardiovascular disease) and one in the less intensive belatacept arm (from infection).
The side effects were also noted for the three groups. The frequency of infections was similar (around 75%) in all three groups. Cancers occurred in two patients treated with intensive belatacept (one breast cancer, and one post-transplantation lymphoproliferative disorder (PTLD)) and in two patients treated with CsA (one skin cancer, and one thyroid cancer). However, PTLD developed in two further patients treated with the intensive regimen 2 and 13 months after the replacement of belatacept with tacrolimus at the end of study. All cases of PTLD were associated with primary Epstein-Barr virus infection or treatment with muromonab-CD3, both of which are known risk factors for the disorder. Approximately half the patients enrolled voluntarily in a long-term extension of the protocol after one year of treatment and no additional case of PTLD occurred after up to four years of follow-up. For metabolic cardiovascular and markers, total, LDL and HDL cholesterol levels were similar in the three groups but signifi cantly more patients in the cyclosporine arm were receiving lipidlowering drugs. Similarly, the percentage of patients treated for hypertension was higher under cyclosporine than under belatacept (92% versus 88 and 83%). The incidence of posttransplantation diabetes mellitus was 8% under cyclosporine and 1% in each belatacept group. The rate of discontinuation was similar in the three groups (22%, 25% and 27%).
In summary, belatacept belongs to a new class of immunosuppressants and is the fi rst maintenance drug to have an immune specifi city. Contrary to many biological agents used for induction or treatment of acute rejection (murumonab, thymoglobulin), belatacept does not appear to act by depleting T-cells or to affect number and function of regulatory T-cells (Moreland et al 2002; Hirose et al 2004; Chavez et al 2007) . Although its long-term safety remains to be confi rmed, its administration is well tolerated and seems to protect patients against adverse renal, cardiovascular and metabolic effects encountered with calcineurin inhibitors, whilst providing equally effective immunosuppression. Furthermore, this totally calcineurin inhibitor-free regimen is the fi rst to be associated with a very low risk of acute rejection. The more disappointing aspect is the need to combine belatacept with standard immunosuppressants (basiliximab, steroids and mycophenolate mofetil). This may explain the similar rates of infection in the three groups and possibly the unanticipated incidence of PTLD in the belatacept arm. Indeed, the absence of infectious and neoplasic complications observed in rheumatoid arthritis with abatacept and belatacept (in studies against placebo) suggests that the side effects reported in renal transplant patients are due to drugs associated with belatacept (Moreland et al 2002) .
Targeting novel costimulatory pathways
It is now apparent that T-cell activation and transplant rejection may proceed in the absence of CD28/B7 and CD40/CD40L signaling. Memory T-cells (London et al 2000; Valujskikh et al 2002) and CD8 + effector T-cells (Ensminger et al 2000) , which play a major role in rejection, are less susceptible to this classical costimulatory blockade. Several other members of the CD28/B7 and TNF/TNF-Receptor (TNF-R) superfamilies deliver positive or negative costimulatory signals, early or late after encountering antigen (Table 3) . These signals are not limited to T-cell/APC interactions, but also involve interplay between T-cells and other T-cells, B-cells or parenchymal cells. Several of these molecules have been targeted in animal models of transplantation.
In the B7/CD28 superfamily, the Induced Costimulatory Molecule (ICOS) and Programmed Death-1 (PD-1) share homology with CD28. However, unlike CD28 these two molecules are not expressed on naïve T-cells but are induced on T-cells after activation. Thus, ICOS signaling is required for the activation and function of effector and memory T-cells, whereas CD28 primes naïve T-cells (Coyle et al 2000) . PD-1 expression is not restricted to T-cells like other members of the CD28 family (Greenwald et al 2005) . Its two ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC) are also constitutively expressed on a large panel of non-lymphoid organs, suggesting a peripheral regulation of self-reactive T-or B-cells. PD-1 ligation transmits a potent inhibitory signal in the early stages of T-cell activation. B7-H3 is a B7 homolog inducible in APCs, which binds a putative receptor on T-cells, resulting in increased T-cell proliferation.
Simplistically, TNF-R-family members are expressed by T-cells and their ligands are expressed by APCs (Table 3) (Croft 2003) . TNF-R/TNF interactions are critical for the clonal expansion/effector phases of immune responses, and involve DC/T-cell and B/T-cell interactions. TNF-Rs may be either constitutively expressed by naïve T-cells, as is the case for CD27, or induced after antigen recognition, as are OX40, 4-1BB, and CD27. Their ligands OX40L, 4-1BBL, and CD70 are not constitutively expressed by APCs but are induced simultaneously with their receptors on T-cells, one to several days after activation (Croft 2003) . Despite variability in expression, binding to TNF-Rs increases cytokine secretion and the proliferation of T-cells receiving the TCR signal (Croft 2003) .
The pair of costimulatory molecules B-and T-lympocyte attenuator (BTLA)/herpervirus-entry mediator (HVEM) is unique in the fact that their interaction bridges the two superfamilies of receptors, CD28 for BTLA and TNF-R for HVEM. This crosstalk is unusual because BTLA is known to inhibit T-cell responses whereas HVEM is an activator receptor (Murphy et al 2006) . Their widespread expression (Table 3) suggests a regulatory role for many cell types. Few and contradictory data are available about the role of BTLA in allogeneic response. Tao et al have shown that targeting of BTLA with a blocking antibody prompted rapid rejection of partially MHC-mismatched murine heart allografts whereas it prolonged survival of fully MHC-mismatched allografts (Tao et al 2005) . The role of BTLA and its ligand has to be precised by further experimental models.
The use of single agents blocking costimulation has proved to be insuffi cient in stringent models of transplantation. In particular, the results obtained with LEA29Y in NHP models of kidney transplantation led investigators to combine it with conventional immunosuppressive reagents for clinical applications so as to minimize the risk of acute rejection Vincenti et al 2005) . Given the diversity, redundancy and complementary nature of all the various costimulation molecules described above, strategies for human transplantation in the future may involve the simultaneous blockade of several selected pathways or the concomitant use of currently approved conventional immunosuppressants.
Future directions for costimulation blockade
In conclusion, a short course of a costimulation-blocking agent to achieve drug-free antigen-specifi c tolerance in transplantation patients does not appear to be a realistic goal in the immediate future. However, costimulation blockade with belatacept has proved to be a powerful alternative to calcineurin inhibitors, and the non-immune side effects and consequences on graft and patient survival can therefore be avoided. This molecule is currently being evaluated in phase III trials versus cyclosporine in recipients of extended-criteria donor kidneys.
Nevertheless, there are issues that require careful consideration at this stage of development: 1. The short half-life of classical oral immunosuppressive drugs implies a relative reversibility of their effects, and this is a major point in cases of malignant or infectious complications. Future trials need to determine whether the long half-life of biological agents precludes their safety. In the belatacept trial, the three PTLD affecting patients receiving belatacept were not expected, and indicate that this new agent does not provide specifi c immunosuppression and may block immune surveillance of tumors. These patients should be carefully followed-up because the long-term safety of belatacept is not known. 2. More practically, although some patients are happy to take fewer tablets each day, the intravenous route of administration makes the ambulatory follow-up of transplant patients more complicated. The development of subcutaneous delivery systems is an essential step if the use of these agents is to become more generalized. In our experience, patients found intravenous administration of belatacept every one or two months acceptable, because they have to come to the hospital for medical visits anyway, and this meant that they had fewer tablets to take. Indeed, the list of drugs that a transplant patient has to take to treat the side-effects of immunosuppressive molecules is long and may result in non-adherence with treatment; this is an established risk factor for late allograft failure. (Humar et al 1999) 3. The best use of costimulation blocking agents in the long term needs to be determined, and it is not known such long-term use has an effect, positive or negative, on the process of accommodation, in other words whether it is possible to give lower doses over time as is the case for drugs currently in use.
4. Monitoring tools adapted to these costimulation blocking agents are required, as with other immunosuppressants. For example, monitoring of belatacept concentrations in blood is possible and studies are necessary to fi nd out whether there is a correlation with the incidence of acute rejection. It is clear that single therapy cannot currently be used, probably because of the redundancy of the various costimulation pathways. Consequently, costimulation blocking agents are actually envisioned as components of combination therapy. The need to use additional drugs may be responsible for a rate of infectious and neoplasic complications that is similar to that observed in classical protocols. Consequently, combined targeting of several costimulation pathways of both B7/CD28 and TNF/TNF-R families could result in a reinforced immunosuppression whilst retaining a degree of immune specifi city. Experimental transplantation models using agonists or blocking reagents have already been used to investigate most of these pathways, and several appear to be attractive targets for future clinical applications. Further studies are necessary to determine how important these new pathways are in the human alloimmune response.
